Novo nordisk a/s: semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and mash resolution in the essence trial

BagsvÆrd, denmark, 1 november 2024 – novo nordisk today announced the headline results from part 1 of the ongoing essence trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis (mash) and moderate to advanced liver fibrosis (stage 2 or 3)1. part 1 of the essence trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology) compared to placebo on top of standard of care for the first 800 randomised people at 72 weeks.
NVO Ratings Summary
NVO Quant Ranking